Mark A.  Kay is the Dennis Farrey Family Professor in Pediatrics and a Professor of Genetics at Stanford University School of Medicine, where he heads the division of human gene therapy. Professor Kay has made seminal contributions in the fields of nucleic acid therapeutics, genome editing,  RNAi therapeutics, and non-coding RNA biology. His work spans basic research through clinical trial research that includes the first systemic delivery of AAV into humans. He has published 300 research articles.  As a founder of the American Society of Gene and Cell Therapy, Dr. Kay served as the society’s 9th president in 2006,  and was the recipient of its Outstanding Achievement Award in 2013. He is currently a deputy editor of Human Gene Therapy and serves on the editorial boards of other peer-reviewed publications. He was elected to the National Academy of Inventors in 2020. Professor Kay has served as a graduate student/post-doctoral/mentor to many current members of ASGCT and ESGCT who are active in academia and industry.